ArticleMolecular therapy oncolytics2021

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML.

Yanjun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.